D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies (NASDAQ:CLGN)

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They presently have a $12.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 447.95% from the stock’s current price.

CLGN has been the subject of several other research reports. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Thursday, August 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CollPlant Biotechnologies has an average rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Stock Performance

Shares of NASDAQ:CLGN opened at $2.19 on Friday. The company has a market capitalization of $27.85 million, a P/E ratio of -1.94 and a beta of 1.38. The company’s 50-day moving average is $2.30 and its 200 day moving average is $2.22. CollPlant Biotechnologies has a fifty-two week low of $1.31 and a fifty-two week high of $4.98.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings data on Wednesday, November 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.65). The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $16.52 million. CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%. As a group, research analysts predict that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Institutional Investors Weigh In On CollPlant Biotechnologies

Several institutional investors have recently made changes to their positions in the stock. AMH Equity Ltd boosted its holdings in shares of CollPlant Biotechnologies by 28.7% in the second quarter. AMH Equity Ltd now owns 160,849 shares of the company’s stock worth $219,000 after acquiring an additional 35,849 shares during the period. Pinnacle Associates Ltd. raised its stake in shares of CollPlant Biotechnologies by 3.7% during the 2nd quarter. Pinnacle Associates Ltd. now owns 507,193 shares of the company’s stock valued at $690,000 after purchasing an additional 18,000 shares during the period. Finally, Villere ST Denis J & Co. LLC lifted its holdings in CollPlant Biotechnologies by 13.0% during the 2nd quarter. Villere ST Denis J & Co. LLC now owns 546,867 shares of the company’s stock worth $744,000 after purchasing an additional 63,000 shares in the last quarter. Hedge funds and other institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.